Tuesday, September 8, 2009
So much for MDS’ plans to focus its Pharma Services unit on early-stage drug development.
According to an Orange Paper released by Russia-based CRO, Synergy Research Group, Russia’s health agency, the Federal Service on Surveillance in Healthcare and Social Development (RosZdraNadzor, RZN) approved only 129 new clinical trials, including local and bioequivalence studies, during Q2 2009, representing a 17% decrease from Q2 last year. The percentage of approved multinational clinical trials increased slightly, however, to 65% of the total during this time period.
CenterWatch, Thought Leaders Mark 15 Years of Industry Growth